证券研究报告 2025 年 06 月 30 日 | 市场数据 | | | | --- | --- | --- | | 指数名称 | 收盘 | 涨跌% | | 上证指数 | 3424.23 | -0.70 | | 深证成指 | 10378.55 | 0.34 | | 创业板指 | 2124.34 | 0.47 | | 科创 50 | 988.21 | -0.18 | | 北证 50 | 1439.63 | 1.06 | | 沪深 300 | 3921.76 | -0.61 | 【财经要闻】香港：稳定币有望为资本市场带来变革，将推动发行人把 稳定币应用推广至不同场景 A 股市场概览 | 类别 | 总市值 | 流通市 | 市盈率 | 市净率 | | --- | --- | --- | --- | --- | | | (亿元) | 值(亿元) | PE | PB | | 上证指数 | 664858 | 515877 | 12.27 | 1.27 | | 深证成指 | 227623 | 186544 | 20.22 | 2.14 | | 创业板指 | 59537 | 47171 | 27.77 | 3.86 | | 科 ...

华纳药厂公告，公司收到国家药品监督管理局核准签发的关于复合磷酸氢钾注射液的《药品补充申请批 准通知书》。复合磷酸氢钾注射液主要用于纠正成人和儿童患者的低磷血症，以及成人和儿童患者的肠 外营养。该药品通过仿制药质量和疗效一致性评价，将有利于市场销售和市场竞争。 ...

Core Viewpoint - Hubei Kelun Pharmaceutical has received approval for its generic drug, Compound Potassium Hydrogen Phosphate Injection, which is now recognized as the second domestic company to pass the consistency evaluation for this product [1][5]. Group 1: Product Overview - Compound Potassium Hydrogen Phosphate Injection is primarily used as a phosphorus supplement in total parenteral nutrition therapy for patients who need to fast for more than five days due to moderate or major surgeries or other traumas [3]. - The sales of this product exceeded 300 million yuan in 2023, marking a year-on-year growth of 33.55%. In the first two quarters of 2024, sales already surpassed 200 million yuan, with a year-on-year growth rate of 33% [3]. Group 2: Market Competition - A total of 11 companies, including Shijiazhuang Fourth Pharmaceutical and Tianjin Pharmaceutical, hold production licenses for Compound Potassium Hydrogen Phosphate Injection, with Shijiazhuang Fourth Pharmaceutical being the first to pass the evaluation [5]. - There are 30 companies, including Shandong Hualu Pharmaceutical and Chenxin Pharmaceutical, that have submitted applications for the generic version of this product, indicating a competitive market landscape [6]. Group 3: Company Achievements - Since 2025, Kelun Pharmaceutical (including subsidiaries) has had 13 products approved, including Tacrolimus Sustained-Release Capsules and Chloride Injection, with some being the first to pass the evaluation for their respective categories [8].